Cancer Letters

Cancer Letters

Volume 248, Issue 1, 8 April 2007, Pages 18-23
Cancer Letters

Mini-review
The structure of the vascular network of tumors

https://doi.org/10.1016/j.canlet.2006.06.007Get rights and content

Abstract

Tumor blood vessels display many structural and functional abnormalities. Their unusual leakiness, potential for rapid growth and remodeling, and expression of distinctive surface molecules mediate the dissemination of tumor cells in the bloodstream and maintain the tumor microenvironment. Like normal blood vessels, they consist of endothelial cells, mural cells and their enveloping basement membrane. Common features, irrespective of their origin, size and growth pattern, are absent hierarchy, formation of large-caliber sinusoidal vessels and markedly heterogeneous density. This review will focus on the factors influencing this heterogeneity.

Introduction

Tumor blood vessels are irregular in size, shape, and branching pattern, lack the normal hierarchy and do not display the recognizable features of arterioles, capillaries or venules. Their haphazard branching patterns and larger, less regular diameters contribute to the non-uniform perfusion of tumor cells.

Abnormalities are present in all components of the vessels wall. The organ and tissue-specific vascular architecture is not retained. Even large caliber vessels are mainly composed of just an endothelium and a basement membrane (BM).

Vessel density is very heterogeneous: the highest values are usually found in what is commonly known as the invading tumor edge, where the density is four to ten times greater than inside the tumor [1]. The arrangement of vessels in the centre of a tumor is much more chaotic than at its edges.

Section snippets

Tumor endothelial cell (EC) features

EC of mature, quiescent vessels are characteristically low proliferative and their estimated turnover times are measured in years, whereas those of tumor vessels are markedly dependent on growth factors for survival. Vascular endothelial growth factor (VEGF) has been convincing assigned a central role in the induction of host vessels into a growing tumor. When EC invade a newly formed tumor, they come into contact with tumor cells that produce VEGF, which may be responsible not only for

Tumor BM

The BM that envelops EC and pericytes (PC) of tumor vessels may have extra layers that have no apparent association with the cells [8]. It contains distinctive forms of fibronectin comprising the ED-B domain, and type IV collagen with exposed cryptic sites [9], and is a source of angiogenic and antiangiogenic molecules. Some of its structural proteins are broken down by enzymes to yield molecules with potent actions. Three examples are endostatin, which is a COOH-terminal fragment of collagen

Tumor PC

PC are perivascular cells that are thought to surround and stabilize new vessels. They extend thin processes around and along the microvascular tubes and have areas of direct contact with EC.

They are revealed by immunohistochemical staining of sections [12] and may cover 73–92% of endothelial sprouts in several murine tumor types. Breast and colon tumors recruit significantly more PC than gliomas or renal cell carcinoma [13].

Most tumor PC are loosely associated with EC, have abnormal shape,

Tumor lymphatic vessels

Convincing evidence for tumor lymphangiogenesis has begun to accumulate and show that it can be stimulated in a variety of experimental cancers by VEGF-C and VEGF-D that signal via VEGF receptor-3 (VEGFR-3) [22]. VEGF-C overexpression led to lymphangiogenesis and growth of the draining lymphatic vessels, intralymphatic tumor growth and lymph node metastasis in several tumor models [23] and clinicopathological studies have reported that expression of VEGF-C, VEGF-D or VEGFR-3 can correlate with

Vascular co-option

Holash et al. [29] reported that tumor cells migrate to host organ blood vessels in sites of metastases, or in vascularized organs such as the brain, and initiate blood-vessel-dependent tumor growth as opposed to classic angiogenesis. These vessels then regress owing to apoptosis of the constituent EC, apparently mediated by Ang-2. Lastly, at the periphery of the growing tumor mass angiogenesis occurs by cooperative interaction of VEGF and Ang-2.

Tumor cells often appear to have immediate access

Vasculogenic mimicry

Maniotis et al. [31] described a new model of formation of vascular channels by human melanoma cells and called it “vasculogenic mimicry” to emphasize the de novo generation of blood vessels without the participation of EC and independent of angiogenesis. Microarray gene chip analysis of a highly aggressive compared with poorly aggressive human cutaneous melanoma cell lines revealed a significant increase in the expression of laminin 5 and MMP-1, MMP-2, MMP-9 and MT1-MMP in the highly

The role of bone marrow-derived stem cells in tumor angiogenesis

Bone marrow-derived stem cells may be a source of endothelial precursor cells (EPC) recruited for tumor-induced neovascularization. High levels of VEGF produced by tumors may result in mobilization of these cells in the peripheral circulation and enhance their recruitment into the tumor vasculature [35]. Moreover, Hattori et al. [36] showed that combined elevation of VEGF and Ang-1 result in remodeling of the bone architecture, with depletion of the sinusoidal spaces of hematopoietic cells and

Vascular targeting to the tumor vasculature

EC lining tumor blood vessels express several cell surface markers that are absent in quiescent blood vessels. Ligand-directed vascular targeting can be accomplished by antibodies, specific peptides or growth factors complexed with immunomodulatory, procoagulant or cytotoxic molecules [40].

Antigenic determinants that are selectively and constitutively expressed on the tumor vasculature include endoglin, VEGF receptors, αν integrins, the fibronectin EDB domain, and prostate-specific membrane

Acknowledgements

Supported by Associazione Italiana per la Ricerca sul Cancro AIRC (National and Regional Funds) Milan, Fondazione Italiana per la Lotta al Neuroblastoma, Genoa, FIRB 2001 and PRIN 2005, Rome, Italy.

References (43)

  • H. Daldrup et al.

    Correlation of dynamic contrast-enhanced MR imaging with histologic tumor grade: comparison of macromolecular and small-molecular contrast media

    A.J.R. Am. J. Roentgenol.

    (1998)
  • D.M. Mc Donald et al.

    Imaging of angiogenesis: from microscope to clinic

    Nat. Med.

    (2003)
  • H.F. Dvorak et al.

    Identification and characterization of the blood vessel of solid tumors that are leaky to circulating macromolecules

    Am. J. Pathol.

    (1988)
  • A. Magnussen et al.

    Rapid access of antibodies to α5β1 integrin overexpressed on the luminal surface of tumor blood vessels

    Cancer Res.

    (2005)
  • St.B. Croix et al.

    Gene expressed in human tumor and endothelium

    Science

    (2000)
  • M. Santamaria et al.

    Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer

    Clin. Cancer Res.

    (2003)
  • P.C. Colorado et al.

    Anti-angiogenic cues from vascular basement membrane collagen

    Cancer Res.

    (2000)
  • R. Kalluri

    Basement membranes: structure, assembly and role in tumor angiogenesis

    Nat. Rev. Cancer

    (2003)
  • A. Eberhard et al.

    Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies

    Cancer Res.

    (2000)
  • P. Guo et al.

    Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment

    Am. J. Pathol.

    (1985)
  • A. Abramsson et al.

    Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors

    J. Clin. Invest.

    (2003)
  • Cited by (101)

    • Bacteria and bacterial derivatives as delivery carriers for immunotherapy

      2022, Advanced Drug Delivery Reviews
      Citation Excerpt :

      Intravenous injection involves direct delivery into the systemic circulation without delay and achieves a more rapid therapeutic effect than any other route [236]. In particular, tumor endothelial cells proliferate rapidly, making fewer tight connections than cells in normal tissue, making it easier for bacteria to pass through tumor blood vessels [237]. Preclinical studies have shown promising results regarding the intravenous injection of various bacterial species, including S. typhimurium [34,135,238], Shigella flexneri [239], E. coli [125], and Bifidobacterium bifidum [240].

    View all citing articles on Scopus
    View full text